The results didn’t add up.
BridgeBio Pharma, a young biotech trying to bring its first big drug to market, followed the blueprint of one of the world’s largest pharmaceutical companies. It made a medicine meant to work like the one that company, Pfizer, had developed for a deadly, genetic heart condition. The biotech also designed a similar kind of trial to test it and expected similarly positive results.
What BridgeBio got instead was a shock.
